In yesterday’s Wall Street session, BioNTech SE (NASDAQ:BNTX) shares traded at $121.75, up 0.68% from the previous session.
17 analysts cover BioNTech SE (NASDAQ:BNTX), according to research data. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $236.29 and a low of $91.35, we find $140.30. Given the previous closing price of $120.93, this indicates a potential upside of 16.02 percent. BNTX stock price is now 11.06% away from the 50-day moving average and -5.30% away from the 200-day moving average. The market capitalization of the company currently stands at $29.00B.
The stock has received a hold rating from 6 analysts and a buy rating from 11. Brokers who have rated the stock have averaged $142.47 as their price target over the next twelve months.
With the price target of $124, HSBC Securities recently initiated with Buy rating for BioNTech SE (NASDAQ: BNTX).
A total of 65.11% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in BNTX stock. A new stake in BioNTech SE shares was purchased by BALYASNY ASSET MANAGEMENT L.P. during the first quarter worth $18,704,000. SCHONFELD STRATEGIC ADVISORS LLC invested $9,947,000 in shares of BNTX during the first quarter. In the first quarter, GTS SECURITIES LLC acquired a new stake in BioNTech SE valued at approximately $7,117,000. WOODLINE PARTNERS LP acquired a new stake in BNTX for approximately $5,576,000. INTEGRAL HEALTH ASSET MANAGEMENT, LLC purchased a new stake in BNTX valued at around $4,383,000 in the second quarter. In total, there are 489 active investors with 17.00% ownership of the company’s stock.
On Friday morning BioNTech SE (NASDAQ: BNTX) stock kicked off with the opening price of $122.82. During the past 12 months, BioNTech SE has had a low of $95.50 and a high of $188.99. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 10.60, and a quick ratio of 10.30. The fifty day moving average price for BNTX is $109.92 and a two-hundred day moving average price translates $128.36 for the stock.
The latest earnings results from BioNTech SE (NASDAQ: BNTX) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.85, beating analysts’ expectations of -$1.04 by 0.19. This compares to $6.86 EPS in the same period last year. The net profit margin was 47.60% and return on equity was 22.30% for BNTX. The company reported revenue of $182.86 million for the quarter, compared to $3.4 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -94.62 percent. For the current quarter, analysts expect BNTX to generate $1.35B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 06/17/2022. Investors who held shares on 06/03/2022 were paid a $2.111 dividend.
BioNTech SE(BNTX) Company Profile
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors; and BNT312, which is in Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase II clinical trial to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.
